BIBLIOGRAFÍA
Martine Denis ha recogido en un pdf toda la evidencia actualizada en última consulta el 12/03/20 con sus links correspondientes, mucho del material que hemos recopilado viene de su documento que fue el punto de inicio para el nuestro:
https://rega.kuleuven.be/if/pdf_corona
1. Gardner EG, Kelton D, Poljak Z, Van Kerkhove M, von Dobschuetz S, Greer AL. A case-crossover analysis of the impact of weather on primary cases of Middle East respiratory syndrome. BMC Infect Dis [Internet]. 2019 Feb 4;19(1):113. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30717685
2. Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. Int J Gen Med [Internet]. 2014;7:417–23. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25187734
3. Wang M JA et al. Temperature Significantly Change COVID-19 Transmission in 429 cities. Pendiente de envio [Internet]. 2020; Available from: https://www.medrxiv.org/content/10.1101/2020.02.22.20025791v1.full.pdf
4. Luo, W., Majumder, M.S., Liu, D. et al. The role of absolute humidity on transmission rates of the COVID-19 outbreak. Pendiente de envio [Internet]. Available from: https://www.medrxiv.org/content/10.1101/2020.02.12.20022467v1
5. Tobías A, Molina T. Is temperature reducing the transmission of COVID-19 ? Environ Res [Internet]. 2020 Jul;186:109553. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0013935120304461
6. Arias-Reyes C, Zubieta-DeUrioste N, Poma-Machicao L, Aliaga-Raudan F, Carvajal-Rodriguez F, Dutschmann M, et al. Does the pathogenesis of SAR-CoV-2 virus decrease at high-altitude? Respir Physiol Neurobiol [Internet]. 2020 Apr;103443. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1569904820301014
7. Zou L, Ruan F, Huang M, Liang L, Huang H, Hong Z, et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N Engl J Med [Internet]. 2020 Feb 19;382(12):NEJMc2001737. Available from: http://www.nejm.org/doi/10.1056/NEJMc2001737
8. Xia J, Tong J, Liu M, Shen Y, Guo D. Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS‐CoV‐2 infection. J Med Virol [Internet]. 2020 Mar 12;jmv.25725. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25725
9. Sun C, Liu Z, Province Z, Hospital SA. Conjunctiva is not a preferred gateway of entry for SARS-CoV-2 to infect respiratory tract. :0–2.
10. Zhang W, Du R-H, Li B, Zheng X-S, Yang X-L, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect [Internet]. 2020 Dec;9(1):386–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32065057
11. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A, Williamson BN, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1. N Engl J Med [Internet]. 2020 Mar 17;NEJMc2004973. Available from: http://www.nejm.org/doi/10.1056/NEJMc2004973
12. Kampf G, Todt D, Pfaender S, Steinmann E. Persistence of coronaviruses on inanimate surfaces and their inactivation with biocidal agents. J Hosp Infect [Internet]. 2020 Mar;104(3):246–51. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0195670120300463
13. Liu Y, Ning Z, Chen Y, Guo M, Liu Y, Gali NK, et al. Aerodynamic analysis of SARS-CoV-2 in two Wuhan hospitals. Nature [Internet]. 2020 Apr 27; Available from: http://www.nature.com/articles/s41586-020-2271-3
14. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. N Engl J Med. 2020;1–9.
15. Men K, Wang X, Zhang G, Hu J, Gao Y, Han H. Estimate the incubation period of coronavirus 2019 ( COVID-19 ). 2020;2019.
16. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann Intern Med [Internet]. 2020;2019. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32150748
17. Liu Y, Eggo RM, Kucharski AJ. Secondary attack rate and superspreading events for SARS-CoV-2. Lancet [Internet]. 2020 Mar;395(10227):e47. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620304621
18. Stein RA. Super-spreaders in infectious diseases. Int J Infect Dis [Internet]. 2011 Aug;15(8):e510–3. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1201971211000245
19. Li Y-K, Peng S, Li L-Q, Wang Q, Ping W, Zhang N, et al. Clinical and Transmission Characteristics of Covid-19 — A Retrospective Study of 25 Cases from a Single Thoracic Surgery Department. Curr Med Sci. 2020;40(2):1–6.
20. Chang D, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, et al. Epidemiologic and Clinical Characteristics of Novel Coronavirus Infections Involving 13 Patients Outside Wuhan, China. JAMA [Internet]. 2020 Feb 7; Available from: https://jamanetwork.com/journals/jama/fullarticle/2761043
21. Bai Y, Yao L, Wei T, Tian F, Jin D-Y, Chen L, et al. Presumed Asymptomatic Carrier Transmission of COVID-19. JAMA [Internet]. 2020 Apr 14;323(14):1406. Available from: https://jamanetwork.com/journals/jama/fullarticle/2762028
22. He X, Lau EH, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. medRxiv [Internet]. 2020;2020.03.15.20036707. Available from: https://www.medrxiv.org/content/10.1101/2020.03.15.20036707v2
23. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China. Sci China Life Sci [Internet]. 2020 Mar 4; Available from: http://link.springer.com/10.1007/s11427-020-1661-4
24. Lan L, Xu D, Ye G, Xia C, Wang S, Li Y, et al. Positive RT-PCR Test Results in Patients Recovered From COVID-19. JAMA [Internet]. 2020 Feb 27; Available from: https://jamanetwork.com/journals/jama/fullarticle/2762452
25. Hsu L, Chia P, Vasoo S. A midpoint perspective on the COVID-19 pandemic. Singapore Med J [Internet]. 2020 Mar 25;51(1):1–1. Available from: http://www.smj.org.sg/sites/default/files/CO-2020-086-epub.pdf
26. Siddiqi HK, Mehra MR. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J Hear Lung Transplant [Internet]. 2020; Available from: https://doi.org/10.1016/j.healun.2020.03.012
27. Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J [Internet]. 2020;2020. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32227120
28. B. Hunt; A. Retter. Practical guidance for the prevention of thrombosis and managementof coagulopathy and disseminated intravascular coagulation of patient infected with COVID-19. [Internet]. March. 2020. Available from: https://b-s-h.org.uk/media/18171/th-and-covid-25-march-2020-final.pdf
29. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls [Internet]. 2020 Mar; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32150360
30. Version T. Diagnosis and Treatment Plan for COVID-19 (Trial Version 6). Chin Med J (Engl) [Internet]. 2020 Mar;2019:1. Available from: http://journals.lww.com/10.1097/CM9.0000000000000819
31. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of 50466 hospitalized patients with 2019-nCoV infection. J Med Virol [Internet]. 2020;(February):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32108351
32. WHO. Consejos actualizados de la OMS para el transporte internacional en relación con el brote del nuevo coronavirus 2019-nCoV [Internet]. [cited 2020 Mar 15]. Available from: https://www.who.int/ith/2019-nCoV_advice_for_international_traffic/es/
33. Guan W-J, Ni Z-Y, Hu YY-H, Liang W-H, Ou C-Q, He J-X, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020 Feb 28;1–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32109013
34. Song F, Shi N, Shan F, Zhang Z, Shen J, Lu H, et al. Emerging 2019 Novel Coronavirus (2019-nCoV) Pneumonia. Radiology [Internet]. 2020 Feb 6;200274. Available from: http://pubs.rsna.org/doi/10.1148/radiol.2020200274
35. Zhang J, Zhou L, Yang Y, Peng W, Wang W, Chen X. Therapeutic and triage strategies for 2019 novel coronavirus disease in fever clinics. Lancet Respir Med [Internet]. 2020 Mar;8(3):e11–2. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32061335
36. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet [Internet]. 2020 Feb;395(10223):507–13. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0140673620302117
37. Gaythorpe K, Imai N, Cuomo-dannenburg G, Baguelin M, Bhatia S, Boonyasiri A, et al. Symptom progression of COVID-19. Imp Coll London COVID-19 Response Team. 2020;(11 March):1–10.
38. Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province,China. medRxiv. 2020;2020.02.17.20024018.
39. Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The first case of 2019 novel coronavirus pneumonia imported into korea from wuhan, china: Implication for infection prevention and control measures. J Korean Med Sci. 2020;35(5):1–4.
40. Chu J, Yang N, Wei Y, Yue H, Zhang F, Zhao J, et al. Clinical Characteristics of 54 medical staff with COVID-19: A retrospective study in a single center in Wuhan, China. J Med Virol [Internet]. 2020 Mar 29; Available from: http://doi.wiley.com/10.1002/jmv.25793
41. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) [Internet]. 2020;6736(20):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32171076
42. Li Y-C, Bai W-Z, Hashikawa T. The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients. J Med Virol [Internet]. 2020 Feb 27; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32104915
43. Esposito G, Pesce M, Seguella L, Sanseverino W, Lu J, Sarnelli G. Can the enteric nervous system be an alternative entrance door in SARS-CoV2 neuroinvasion? Brain Behav Immun [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0889159120306449
44. Mao L, Wang M, Chen S, He Q, Chang J, Hong C, et al. Neurological Manifestations of Hospitalized Patients with COVID-19 in Wuhan, China: a retrospective case series study. medRxiv. 2020;2020.02.22.20026500.
45. Toscano G, Palmerini F, Ravaglia S, Ruiz L, Invernizzi P, Cuzzoni MG, et al. Guillain–Barré Syndrome Associated with SARS-CoV-2. N Engl J Med [Internet]. 2020 Apr 17;NEJMc2009191. Available from: http://www.nejm.org/doi/10.1056/NEJMc2009191
46. Sociedad Española Neurologia. Recomendaciones de la Sociedad Española de Neurología (SEN) en relación con la pérdida de olfato como posible síntoma precoz de infección por CoVID-19 [Internet]. 2020. Available from: http://www.sen.es/attachments/article/2663/Recomendaciones de la Sociedad Española de Neurología (SEN) en relación con la pérdida de olfato como posible síntoma precoz de infección por CoVID-19.pdf
47. Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: Implications for clinicians and researchers. Eur Respir J [Internet]. 2020 Apr 27;2001028. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01028-2020
48. Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury with Mortality in Hospitalized Patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;1–8.
49. Chen C, Zhou Y, Wang DW. SARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz [Internet]. 2020 Mar 5; Available from: http://link.springer.com/10.1007/s00059-020-04909-z
50. Pan L, Mu M, Ren HG, Yang P. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei , China : a descriptive , cross-sectional , multicenter study. Am J Gastroenterol. 2020;
51. Tian Y, Rong L, Nian W, He Y. Review article: Gastrointestinal features in COVID-19 and the possibility of faecal transmission. Aliment Pharmacol Ther [Internet]. 2020;(March):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32222988
52. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA - J Am Med Assoc. 2020;1–9.
53. Jin X, Lian JS, Hu JH, Gao J, Zheng L, Zhang YM, et al. Epidemiological, clinical and virological characteristics of 74 cases of coronavirus-infected disease 2019 (COVID-19) with gastrointestinal symptoms. Gut. 2020;1–8.
54. Iberoamerica C. En los pacientes con COVID-19 y una sospecha de embolia pulmonar, ¿cuáles son los criterios más útiles para definir su indicación de evaluación con una TC? [Internet]. 2020. [cited 2020 Apr 20]. Available from: https://es.cochrane.org/es/en-los-pacientes-con-covid-19-y-una-sospecha-de-embolia-pulmonar-¿cuáles-son-los-criterios-más
55. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0049384820301201
56. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: A retrospective case study in three hospitals within Wuhan, China. Ann Oncol [Internet]. 2020 Mar; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0923753420363833
57. Li W, Zhang J, Xiao S, Sun L. Characteristics of health worker fatality in China during the outbreak of COVID-19 infection. J Infect [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32277966%0Ahttp://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=PMC7141456
58. Bangalore S, Sharma A, Slotwiner A, Yatskar L, Harari R, Shah B, et al. ST-Segment Elevation in Patients with Covid-19 — A Case Series. N Engl J Med [Internet]. 2020 Apr 17;NEJMc2009020. Available from: http://www.nejm.org/doi/10.1056/NEJMc2009020
59. Cui S, Chen S, Li X, Liu S, Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32271988
60. Bozzani A, Arici V, Franciscone MM, Danesino V, Cascina A, Ticozzelli G, et al. SARSCoV-2 infection and the upper limbs deep vein thrombosis risk. Ann Vasc Surg [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0890509620303563
61. Wang Y, Wang Y, Chen Y, Qin Q. Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID‐19) implicate special control measures. J Med Virol [Internet]. 2020 Mar 5;jmv.25748. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25748
62. Ali H, Daoud A, Mohamed MM, Salim SA, Yessayan L, Baharani J, et al. Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis. Ren Fail [Internet]. 2020 Jan 1;42(1):393–7. Available from: https://www.tandfonline.com/doi/full/10.1080/0886022X.2020.1756323
63. Barazzoni R, Bischoff SC, Breda J, Wickramasinghe K, Krznaric Z, Nitzan D, et al. ESPEN expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr [Internet]. 2020 Mar; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0261561420301400
64. Fernández de Sanmaed MJ, Riera Armengol L SFE. ¿Y después de la fase aguda de la COVID-19 qué? 2a parte. AMF Actual en Med Fam. 2020;
65. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA [Internet]. 2020 Feb 24; Available from: https://jamanetwork.com/journals/jama/fullarticle/2762130
66. Instituto superiore di sanitá. Report sulle caratteristiche dei pazienti deceduti positivi a COVID-19 in Italia.
67. Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med [Internet]. 2020 Mar 3; Available from: http://link.springer.com/10.1007/s00134-020-05991-x
68. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv. 2020 Feb;2020.02.26.20028191.
69. Yanping Zhang. Vigilancias vitales: las características epidemiológicas de un brote de nuevas enfermedades por coronavirus de 2019 (COVID-19) - China, 2020. Web [Internet]. 2020;2(8):113–22. Available from: http://weekly.chinacdc.cn/en/article/id/e53946e2-c6c4-41e9-9a9b-fea8db1a8f51?utm_source=TrendMD&utm_medium=cpc&utm_campaign=China_CDC_Weekly_TrendMD_1
70. Rong-Hui Du, Li-Rong Liang, Cheng-Qing Yang, Wen Wang, Tan-Ze Cao, Ming Li, Guang-Yun Guo, Juan Du, Chun-Lan Zheng, Qi Zhu, Ming Hu, Xu-Yan Li, Peng Peng H-ZS. Early View Original article Predictors of Mortality for Patients with COVID-19 Pneumonia Caused by SARS-CoV-2 : A Prospective Cohort Study. Eur Respir J. 2020;
71. Zhu Z, Cai T, Fan L, Lou K, Hua X, Huang Z, et al. Clinical value of immune-inflammatory parameters to assess the severity of coronavirus disease 2019. Int J Infect Dis [Internet]. 2020 Apr;592:124530. Available from: https://www.ijidonline.com/article/S1201-9712(20)30257-5/pdf
72. Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, et al. [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi [Internet]. 2020 Mar 2;48:E004. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32120458
73. Lighter J, Phillips M, Hochman S, Sterling S, Johnson D, Francois F, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission. Clin Infect Dis [Internet]. 2020 Apr 9;1–29. Available from: https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/ciaa415/5818333
74. Conforti C, Cannavò SP, Jafferany M, Dianzani C, Meo N Di, Lotti T, et al. Coronavirus disease 2019 (COVID-19): facts and controversies. Dermatol Ther [Internet]. 2020 Apr 1;e13366. Available from: http://doi.wiley.com/10.1111/dth.13366
75. Bordi L, Nicastri E, Scorzolini L, Di Caro A, Capobianchi MR, Castilletti C, et al. Differential diagnosis of illness in patients under investigation for the novel coronavirus (SARS-CoV-2), Italy, February 2020. Eurosurveillance [Internet]. 2020;25(8):2–5. Available from: https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.8.2000170
76. Cevik M, Bamford C, Ho A. COVID-19 pandemic – A focused review for clinicians. Clin Microbiol Infect [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1198743X20302317
77. Li Gang, Chen M J, Chen W et al. Variation in the titer of the specific IgG antibody in patients with SARS. Li Gang, Chen M J, Chen W, al. 2003;283–5.
78. Chan KH, Cheng VCC, Woo PCY, Lau SKP, Poon LLM, Guan Y, et al. Serological responses in patients with severe acute respiratory syndrome coronavirus infection and cross-reactivity with human coronaviruses 229E, OC43, and NL63. Clin Diagn Lab Immunol [Internet]. 2005 Nov;12(11):1317–21. Available from: http://www.ncbi.nlm.nih.gov/pubmed/16275947
79. Xun J, Lu L, Jiang S, Lu H, Wen Y, Huang J. patient cohort and their implications. 2020;
80. Bao L, Deng W, Gao H, Xiao C, Liu J, Xue J, et al. Reinfection could not occur in SARS-CoV-2 infected rhesus macaques. bioRxiv. 2020;2020.03.13.990226.
81. Three C, Central G, Public T, Hospital TS, Authors C, Huang A. Antibody responses to SARS-CoV-2 in COVID-19 patients: the perspective application of serological tests in clinical practice. 2020;
82. Qu J, Wu C, Li X, Zhang G, Jiang Z, Li X, et al. Profile of IgG and IgM antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis [Internet]. 2020 Apr 27; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa489/5825506
83. Zhou L, Liu K, Liu HG. Cause analysis and treatment strategies of “recurrence” with novel coronavirus pneumonia (covid-19) patients after discharge from hospital. Zhonghua Jie He He Hu Xi Za Zhi [Internet]. 2020 Mar 2;43:E028. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32118391
84. Ferro F, Elefante E, Baldini C, Bartoloni E, Puxeddu I, Talarico R, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol [Internet]. 38(2):175–80. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32207680
85. Recalcati S. Cutaneous manifestations in COVID-19: a first perspective. J Eur Acad Dermatology Venereol [Internet]. 2020 Mar 26; Available from: http://doi.wiley.com/10.1111/jdv.16387
86. Grimalt DR. Skin manifestations in COVID-19 [Internet]. Twitter. 2020 [cited 2020 Apr 4]. Available from: https://twitter.com/DrRamonGrimalt/status/1244588698047598592
87. Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A, Moreno-Arrones OM, Saceda-Corralo D, Arana-Raja A, et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S019096222030709X
88. Galván Casas C, Català A, Carretero Hernández G, Rodríguez‐Jiménez P, Fernández Nieto D, Rodríguez‐Villa Lario A, et al. Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol [Internet]. 2020 Apr 29;bjd.19163. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjd.19163
89. Bouaziz J, Duong T, Jachiet M, Velter C, Lestang P, Cassius C, et al. Vascular skin symptoms in COVID‐19: a french observational study. J Eur Acad Dermatology Venereol [Internet]. 2020 Apr 27;jdv.16544. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.16544
90. Wu P, Duan F, Luo C, Liu Q, Qu X, Liang L, et al. Characteristics of Ocular Findings of Patients With Coronavirus Disease 2019 (COVID-19) in Hubei Province, China. JAMA Ophthalmol [Internet]. 2020 Mar 31; Available from: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2764083
91. Li J-PO, Lam DSC, Chen Y, Ting DSW. Novel Coronavirus disease 2019 (COVID-19): The importance of recognising possible early ocular manifestation and using protective eyewear. Br J Ophthalmol [Internet]. 2020 Mar 21;104(3):297–8. Available from: http://bjo.bmj.com/lookup/doi/10.1136/bjophthalmol-2020-315994
92. Seah I, Agrawal R. Can the Coronavirus Disease 2019 (COVID-19) Affect the Eyes? A Review of Coronaviruses and Ocular Implications in Humans and Animals. Ocul Immunol Inflamm [Internet]. 2020 Mar 16;1–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32175797
93. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med [Internet]. 2020 Feb 28;NEJMoa2002032. Available from: http://www.nejm.org/doi/10.1056/NEJMoa2002032
94. Sun Y, Koh V, Marimuthu K, Ng OT, Young B, Vasoo S, et al. Epidemiological and Clinical Predictors of COVID-19. Clin Infect Dis. 2020;1–31.
95. Yu CM, Wong RSM, Wu EB, Kong SL, Wong J, Yip GWK, et al. Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J. 2006;82(964):140–4.
96. Di Qi, Xiaofeng Yan, Xumao Tang, Junnan Peng, Qian Yu, Longhua Feng, Guodan Yuan, An Zhang, Yaokai Chen, Jing Yuan, Xia Huang, Xianxiang Zhang, Peng Hu, Yuyan Song, Chunfang Qian, Qiangzhong Sun, Daoxin Wang, Jin Tong JX. Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. 2020; Available from: https://www.medrxiv.org/content/10.1101/2020.03.01.20029397v1.full.pdf
97. Liu L, Gao J. Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China. medRxiv. 2020;2020.02.20.20025536.
98. Jin YH, Cai L, Cheng ZS, Cheng H, Deng T, Fan YP, et al. A rapid advice guideline for the diagnosis and treatment of 2019 novel coronavirus (2019-nCoV) infected pneumonia (standard version). Vol. 7, Military Medical Research. BioMed Central Ltd.; 2020. p. 4.
99. Sun P, Qie S, Liu Z, Ren J, Li K, Xi J. Clinical characteristics of hospitalized patients with {SARS}-{CoV}-2 infection: {A} single arm meta-analysis. J Med Virol. 2020 Feb;
100. Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis [Internet]. 2020;3099(20):1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32105637
101. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506.
102. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. Jama [Internet]. 2020;1–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32125362
103. Chorin E, Padegimas A, Havakuk O, Birati EY, Shacham Y, Milman A, et al. Assessment of Respiratory Distress by the Roth Score. Clin Cardiol. 2016;39(11):636–9.
104. WHO. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2020. Available from: https://www.who.int/docs/default-source/coronaviruse/who-china-joint-mission-on-covid-19-final-report.pdf
105. Best Practice. COVID-19 [Internet]. 12-03-2020. [cited 2020 Mar 28]. Available from: https://bestpractice.bmj.com/topics/en-gb/3000168
106. Wold Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected [Internet]. Geneve; 2020. Available from: https://www.google.com/url?sa=t&rct=j&q=&esrc=s&source=web&cd=2&cad=rja&uact=8&ved=2ahUKEwid8omMi53oAhWpAWMBHdXnB74QFjABegQIBxAB&url=https%3A%2F%2Fwww.who.int%2Fdocs%2Fdefault-source%2Fcoronaviruse%2Fclinical-management-of-novel-cov.pdf%3Fsfvrsn%3Dbc7da51
107. WHO. WHO. Volume 2 IMAI District Clinician Manual. Hospital care for adolescents and adults. Geneve; 2011.
108. BURGE, A. GREEN M, RUSSELL-JONES D. Patient power – Kidd Gloves. Clin Med J R Coll Physicians London [Internet]. 2018;18(5):437–8. Available from: https://www.rcpjournals.org/content/clinmedicine/18/5/437.full.pdf
109. Tomlinson S, Behrmann S, Cranford J, Louie M, Hashikawa A. Accuracy of Smartphone-Based Pulse Oximetry Compared with Hospital-Grade Pulse Oximetry in Healthy Children. Telemed e-Health. 2018;24(7):527–35.
110. Jordan TB, Meyers CL, Schrading WA, Donnelly JP. The utility of iPhone oximetry apps: A comparison with standard pulse oximetry measurement in the emergency department. Am J Emerg Med [Internet]. 2019;(xxxx):158350. Available from: https://doi.org/10.1016/j.ajem.2019.07.020
111. Chan C, Inskip JA, Kirkham AR, Ansermino JM, Dumont G, Li LC, et al. A smartphone oximeter with a fingertip probe for use during exercise training: usability, validity and reliability in individuals with chronic lung disease and healthy controls. Physiother (United Kingdom). 2019;105(3):297–306.
112. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in Different Types of Clinical Specimens. Jama [Internet]. 2020;3–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32159775
113. Qiu L, Liu X, Xiao M, Xie J, Cao W, Liu Z, et al. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection. Clin Infect Dis [Internet]. 2020 Apr 2; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa375/5815295
114. Zhuang GH, Shen MW, Zeng LX, Mi BB, Chen FY, Liu WJ, et al. [Potential false-positive rate among the “asymptomatic infected individuals” in close contacts of COVID-19 patients]. Zhonghua Liu Xing Bing Xue Za Zhi [Internet]. 2020 Mar 5;41(4):485–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32133832
115. Azzi L, Carcano G, Dalla Gasperina D, Sessa F, Maurino V, Baj A. Two cases of COVID‐19 with positive salivary and negative pharyngeal or respiratory swabs at hospital discharge: a rising concern. Oral Dis [Internet]. 2020 Apr 25;odi.13368. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/odi.13368
116. To KK-W, Tsang OT-Y, Yip CC-Y, Chan K-H, Wu T-C, Chan JM-C, et al. Consistent Detection of 2019 Novel Coronavirus in Saliva. Clin Infect Dis [Internet]. 2020 Feb 12; Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa149/5734265
117. Thompson R, Cunniffe N. The probability of detection of SARS-CoV-2 in saliva. Stat Methods Med Res [Internet]. 2020 Apr 26;29(4):1049–50. Available from: http://journals.sagepub.com/doi/10.1177/0962280220915049
118. Inmunología SE de. Utilidad de determinación de anticuerpos anti SARS-CoV-2. Propuesta de implementación como prueba diagnóstica, pronóstica y de desarrollo de inmunidad protectora Versión 01. 2 abril 2020.
119. Chen C, Gao G, Xu Y, Pu L, Wang Q, Wang L, et al. SARS-CoV-2–Positive Sputum and Feces After Conversion of Pharyngeal Samples in Patients With COVID-19. Ann Intern Med [Internet]. 2020 Mar 30; Available from: https://annals.org/aim/fullarticle/2764036/sars-cov-2-positive-sputum-feces-after-conversion-pharyngeal-samples
120. Döhla M, Boesecke C, Schulte B, Diegmann C, Sib E, Richter E, et al. Rapid point-of-care testing for SARS-CoV-2 in a community screening setting shows low sensitivity. Public Health [Internet]. 2020 May;182:170–2. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0033350620301141
121. Cassaniti I, Novazzi F, Giardina F, Salivaro F, Sachs M, Perlini S, et al. Performance of VivaDiagTM COVID-19 IgM/IgG Rapid Test is inadequate for diagnosis of COVID-19 in acute patients referring to emergency room department. J Med Virol [Internet]. 2020 Mar 30; Available from: http://doi.wiley.com/10.1002/jmv.25800
122. SEIMC. Recomendaciones de SEIMC sobre el uso de la las pruebas de detección de anticuerpos. [Internet]. 2020. Available from: https://seimc.org
123. who. Advice on the use of point-of-care inmunodiagnostic tests for COVID-19. Scientific Brief. [Internet]. 2020 [cited 2020 Apr 12]. Available from: https://www.who.int/news-room/commentaries/detail/advice-on-the-use-of-point-of-care-inmunodiagnostic-tests-for-covid-19
124. Sethuraman N, Jeremiah SS, Ryo A. Interpreting Diagnostic Tests for SARS-CoV-2. JAMA [Internet]. 2020 May 6; Available from: https://jamanetwork.com/journals/jama/fullarticle/2765837
125. Liu Y, Yang Y, Zhang C, Huang F, Wang F, Yuan J, et al. Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury. Sci China Life Sci [Internet]. 2020 Mar 9;63(3):364–74. Available from: http://link.springer.com/10.1007/s11427-020-1643-8
126. Liu W, Tao Z-W, Lei W, Ming-Li Y, Kui L, Ling Z, et al. Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl) [Internet]. 2020;0. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32118640
127. Fan Z, Chen L, Li J, Tian C, Zhang Y, Huang S, et al. Clinical Features of COVID-19 Related Liver Damage. medRxiv. 2020;2020.02.26.20026971.
128. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019. medRxiv. 2020;(1095):2020.02.16.20023903.
129. Lippi G, Plebani M. Procalcitonin in patients with severe coronavirus disease 2019 (COVID-19): A meta-analysis. Clin Chim Acta [Internet]. 2020 Jun;505(4546):190–1. Available from: https://doi.org/10.1016/j.cca.2020.03.004
130. Xiong M, Liang X, Wei Y. Changes in Blood Coagulation in Patients with Severe Coronavirus Disease 2019 (COVID‐19): a Meta‐Analysis. Br J Haematol [Internet]. 2020 Apr 18;bjh.16725. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/bjh.16725
131. Velavan TP, Meyer CG. Mild versus severe COVID-19: laboratory markers. Int J Infect Dis [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1201971220302770
132. Guo Y-R, Cao Q-D, Hong Z-S, Tan Y-Y, Chen S-D, Jin H-J, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020 Mar;7(1):11.
133. Cascella M, Rajnik M, Cuomo A, Dulebohn SC, Di Napoli R. Features, Evaluation and Treatment Coronavirus (COVID-19). StatPearls. StatPearls Publishing; 2020.
134. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;
135. Wong HYF, Lam HYS, Fong AH-T, Leung ST, Chin TW-Y, Lo CSY, et al. Frequency and Distribution of Chest Radiographic Findings in COVID-19 Positive Patients. Radiology [Internet]. 2019 Mar 27;201160. Available from: http://pubs.rsna.org/doi/10.1148/radiol.2020201160
136. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. Radiology. 2020 Feb;200642.
137. Peng QY, Wang XT, Zhang LN, Critical C, Ultrasound C, Group S. Findings of lung ultrasonography of novel corona virus pneumonia during the 2019 – 2020 epidemic. Intensive Care Med. 2020;(87):6–7.
138. Soldati G, Smargiassi A, Inchingolo R, Buonsenso D, Perrone T, Briganti DF, et al. Proposal for international standardization of the use of lung ultrasound for COVID-19 patients; a simple, quantitative, reproducible method. J Ultrasound Med [Internet]. 2020 Mar 30; Available from: http://doi.wiley.com/10.1002/jum.15285
139. Erika Poggiali, Alessandro Dacrema, Davide Bastoni, Valentina Tinelli, Elena Demichele, Pau Mateo Ramos, Teodoro Marcianò, Matteo Silva, Andrea Vercelli and AM. Can Lung US Help Critical Care Clinicians in the Early Diagnosis of Novel Coronavirus (COVID-19) Pneumonia? Radiology. 2020;
140. Huang Y WS. A preliminary study on the ultrasoinc manifestations of peripulmonary lesions of non-critical coronavirus pneumonia (COVID-19). 2020;
141. Koibuchi H, Fujii Y, Kotani K, Konno K, Matsunaga H, Miyamoto M, et al. Degradation of ultrasound probes caused by disinfection with alcohol. J Med Ultrason [Internet]. 2011 Apr 23;38(2):97–100. Available from: http://link.springer.com/10.1007/s10396-010-0296-1
142. Echocardiography AS of. Cleaning Recommendations from Ultrasound Manufacturers [Internet]. 2020 [cited 2020 Apr 5]. Available from: https://www.asecho.org/covid-19-resources/cleaning-recommendations-from-ultrasound-manufacturers/
143. Sociedad Española de Ultrasonidos. Realización de ecografías durante la pandemia de COVID-19 medidas de serguridad [Internet]. 2020. Available from: http://www.seus.org/publicaciones-documentos-seus.html
144. SERAM. COVID-19 Lo que el técnico tiene que saber [Internet]. 2020. Available from: https://www.seram.es/images/site/Infección_COVID_19_TER.pdf
145. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, et al. Development and Clinical Application of A Rapid IgM-IgG Combined Antibody Test for SARS-CoV-2 Infection Diagnosis. J Med Virol [Internet]. 2020;0–1. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32104917
146. Kamel Boulos MN, Geraghty EM. Geographical tracking and mapping of coronavirus disease COVID-19/severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic and associated events around the world: how 21st century GIS technologies are supporting the global fight against outbr. Int J Health Geogr [Internet]. 2020;19(1):1–12. Available from: https://doi.org/10.1186/s12942-020-00202-8
147. Mayor S. Covid-19 : Researchers launch app to track spread of symptoms in the UK. 2020;1263(March):2020. Available from: http://dx.doi.org/doi:10.1136/bmj.m1263
148. Park J-E, Ryu Y. Transmissibility and severity of influenza virus by subtype. Infect Genet Evol [Internet]. 2018 Nov;65:288–92. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1567134818306051
149. Allan GM, Arroll B. Prevention and treatment of the common cold: making sense of the evidence. CMAJ [Internet]. 2014 Feb 18;186(3):190–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24468694
150. Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet [Internet]. 2015;386(9997):995–1007. Available from: http://dx.doi.org/10.1016/S0140-6736(19)33221-0
151. CDC. Clinical guidance management patients [Internet]. 2020. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-management-patients.html
152. OMS. Atención en el domicilio de pacientes presuntamente infectados por el nuevo coronavirus ( nCoV ) que tengan síntomas leves y gestión de los contactos. 2020;(1):1–4.
153. Chinese CNH& SA of T. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia. 2020; Available from: https://twitter.com/ChinaEmbEsp/status/1238428791107661824
154. AEMPS. Nota AEMPS Ibuprofeno y Covid-19 [Internet]. 2020. Available from: https://www.aemps.gob.es/informa/notasinformativas/medicamentosusohumano-3/2020-medicamentosusohumano-3/la-aemps-informa-que-ningun-dato-indica-que-el-ibuprofeno-agrave-las-infecciones-por-covid-19/
155. Arranz Izquierdo J MJ. COVID-19 semFYC. 2020; Available from: https://www.semfyc.es/wp-content/uploads/2020/03/covid-19-semFYC.pdf
156. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther [Internet]. 2020;14(1):58–60. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32147628
157. Sheahan TP, Sims AC, Graham RL, Menachery VD, Gralinski LE, Case JB, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med [Internet]. 2017;9(396). Available from: http://www.ncbi.nlm.nih.gov/pubmed/28659436
158. Sheahan TP, Sims AC, Leist SR, Schäfer A, Won J, Brown AJ, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun [Internet]. 2020 Dec 10;11(1):222. Available from: http://www.nature.com/articles/s41467-019-13940-6
159. Ministerio de Sanidad Servicios Sociales e Igualdad. Informe de Posicionamiento Terapéutico de baricitinib (Olumiant®) en artritis reumatoide. 2017.
160. Richardson PJ, Corbellino M, Stebbing J. Baricitinib for COVID-19: a suitable treatment? – Authors’ reply. Lancet Infect Dis [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S147330992030270X
161. Xu X, Han M, Li T, Sun W, Wang D, Fu B, et al. Effective Treatment of Severe COVID-19 Patients with Tocilizumab. 2020;
162. Bennardo F, Buffone C, Giudice A. New therapeutic opportunities for COVID-19 patients with Tocilizumab: Possible correlation of interleukin-6 receptor inhibitors with osteonecrosis of the jaws. Oral Oncol [Internet]. 2020;127(xxxx):104659. Available from: https://doi.org/10.1016/j.oraloncology.2020.104659
163. Ministerio de Sanidad Servicios Sociales e Igualdad. Documento técnico Manejo clínico del COVID-19 : tratamiento médico. 2020;1–23. Available from: https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Protocolo_manejo_clinico_tto_COVID-19.pdf
164. Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment? Clin Infect Dis [Internet]. 2020 Mar 24;53(9):1689–99. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa321/5811416
165. Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care [Internet]. 2020;3–7. Available from: https://www.sciencedirect.com/science/article/pii/S0883944120303907
166. Gautret P, Lagier JC , Parola P VTH et al. Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study Running title: Hydroxychloroquine-Azithromycin and COVID-19. Pendiente de envio [Internet]. 2020; Available from: https://www.mediterranee-infection.com/wp-content/uploads/2020/03/COVID-IHU-2-1.pdf
167. Gautret P , Lagier JC , Parola P, Hoang VT , Meddeb L , Mailhe M et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open- label non-randomized clinical trial Philippe Gautret. :1–24.
168. Zhaowei Chen, , Jijia Hu , Zongwei Zhang, Shan Jiang, Shoumeng Han, Dandan Yan, Ruhong Zhuang BH and ZZ. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. Pendiente de revisión [Internet]. 2020;7. Available from: https://www.medrxiv.org/content/10.1101/2020.03.22.20040758v2.full.pdf
169. AEMPS. La AEMPS informa de la distribución controlada de todo el stock de hidroxicloroquina/cloroquina [Internet]. Available from: https://www.aemps.gob.es/informa/notasinformativas/laaemps/2020-laaemps/la-aemps-informa-de-la-distribucion-controlada-de-todo-el-stock-de-hidroxicloroquina-cloroquina/
170. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med [Internet]. 2020;1–13. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32187464
171. Chen C-Y, Wang F-L, Lin C-C. Chronic Hydroxychloroquine Use Associated with QT Prolongation and Refractory Ventricular Arrhythmia. Clin Toxicol [Internet]. 2006 Jan 7;44(2):173–5. Available from: http://www.tandfonline.com/doi/full/10.1080/15563650500514558
172. Gautret P, Lagier J-C, Parola P, Hoang VT, Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents [Internet]. 2020 Mar;105949. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0924857920300996
173. Lakkireddy DR, Chung MK, Gopinathannair R, Patton KK, Gluckman TJ, Turagam M, et al. Guidance for Cardiac Electrophysiology During the Coronavirus (COVID-19) Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of. Hear Rhythm [Internet]. 2020 Apr 1; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32247013
174. Cardiology AC of. Ventricular Arrhythmia Risk Due to Hydroxychloroquine-Azithromycin Treatment For COVID-19 [Internet]. 2020 [cited 2020 Apr 11]. Available from: https://www.acc.org/latest-in-cardiology/articles/2020/03/27/14/00/ventricular-arrhythmia-risk-due-to-hydroxychloroquine-azithromycin-treatment-for-covid-19
175. John R. Giudicessi , Peter A. Noseworthy, Paul A. Friedman MJA. Urgent Guidance for Navigating and Circumventing the QTc Prolonging and Torsadogenic Potential of Possible Pharmacotherapies for COVID-19 [Internet]. 2020 [cited 2020 Apr 11]. Available from: http://samin.es/wp-content/uploads/2020/03/jmcp_covid19.pdf.pdf.pdf.pdf.pdf
176. Gendrot M, Andreani J JP et at. Short communication In vitro antiviral activity of doxycycline against SARS-CoV-2. Pendiente de envio [Internet]. 2020;19–21. Available from: https://www.mediterranee-infection.com/wp-content/uploads/2020/04/Dox_Covid_pre-print.pdf
177. Götz V, Magar L, Dornfeld D, Giese S, Pohlmann A, Höper D, et al. Influenza A viruses escape from MxA restriction at the expense of efficient nuclear vRNP import. Sci Rep [Internet]. 2016 Mar 18;6(1):23138. Available from: http://www.nature.com/articles/srep23138
178. Lundberg L, Pinkham C, Baer A, Amaya M, Narayanan A, Wagstaff KM, et al. Nuclear import and export inhibitors alter capsid protein distribution in mammalian cells and reduce Venezuelan Equine Encephalitis Virus replication. Antiviral Res [Internet]. 2013 Dec;100(3):662–72. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0166354213002945
179. Wagstaff KM, Rawlinson SM, Hearps AC, Jans DA. An AlphaScreen ® -Based Assay for High-Throughput Screening for Specific Inhibitors of Nuclear Import. J Biomol Screen [Internet]. 2011 Feb;16(2):192–200. Available from: http://journals.sagepub.com/doi/10.1177/1087057110390360
180. Yang SNY, Atkinson SC, Wang C, Lee A, Bogoyevitch MA, Borg NA, et al. The broad spectrum antiviral ivermectin targets the host nuclear transport importin α/β1 heterodimer. Antiviral Res [Internet]. 2020 May;177:104760. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0166354219307211
181. Yamasmith E. et al. Efficacy and safety of ivermectin against dengue infection: a phase III, randomized, double-blind, placebo-controlled trial. 2018.
182. Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res [Internet]. 2020 Jun;178:104787. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0166354220302011
183. Cantini F, Niccoli L, Matarrese D, Nicastri E, Stobbione P, Goletti D. Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact. J Infect [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0163445320302280
184. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223):473–5.
185. Mehta P, Mcauley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, et al. Correspondence COVID-19 : consider cytokine storm syndromes and. Lancet [Internet]. 2020;6736(20):19–20. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30628-0
186. Bousquet J, Akdis C, Jutel M, Bachert C, Klimek L, Agache I, et al. Intranasal corticosteroids in allergic rhinitis in COVID-19 infected patients: An ARIA-EAACI statement. Allergy [Internet]. 2020 Mar 31; Available from: http://doi.wiley.com/10.1111/all.14302
187. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective. Eur Respir J [Internet]. 2020 Apr 27;2001009. Available from: http://erj.ersjournals.com/lookup/doi/10.1183/13993003.01009-2020
188. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost [Internet]. 2020 Feb 19; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32073213
189. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost [Internet]. 2020 Mar 27;March. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32220112
190. Calvo C, García López-Hortelano M, de Carlos Vicente JC, Vázquez Martínez JL, Ramos JT, Baquero-Artigao F, et al. Recomendaciones sobre el manejo clínico de la infección por el «nuevo coronavirus» SARS-CoV2. Grupo de trabajo de la Asociación Española de Pediatría (AEP). An Pediatría [Internet]. 2020 Mar;1(1):1–6. Available from: https://linkinghub.elsevier.com/retrieve/pii/S169540332030076X
191. Mak JWY, Chan FKL, Ng SC. Probiotics and COVID-19: one size does not fit all. Lancet Gastroenterol Hepatol [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S2468125320301229
192. Bloch EM, Shoham S, Casadevall A, Sachais BS, Shaz B, Winters JL, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32254064
193. Maggio R, Corsini GU. Repurposing the mucolytic cough suppressant and TMPRSS2 protease inhibitor bromhexine for the prevention and management of SARS-CoV-2 infection. Pharmacol Res [Internet]. 2020 Apr;104837. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1043661820311452
194. Davino-Chiovatto JE, Oliveira-Junior MC, MacKenzie B, Santos-Dias A, Almeida-Oliveira AR, Aquino-Junior JCJ, et al. Montelukast, Leukotriene Inhibitor, Reduces LPS-Induced Acute Lung Inflammation and Human Neutrophil Activation. Arch Bronconeumol (English Ed [Internet]. 2019 Nov;55(11):573–80. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1579212919302952
195. Agrawal S, Goel A. Prone position ventilation in Acute Respiratory Distress Syndrome: An overview of the evidences. Indian J Anaesth [Internet]. 2015;59(4):246. Available from: http://www.ijaweb.org/text.asp?2015/59/4/246/155004
196. Alhazzani W, Møller MH, Arabi YM, Loeb M, Gong MN, Fan E, et al. Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med [Internet]. 2020 Mar 28; Available from: http://link.springer.com/10.1007/s00134-020-06022-5
197. Rami Sommerstein. Re: Preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19. BMJ [Internet]. 2020 Feb 28;360:m810. Available from: https://www.bmj.com/content/368/bmj.m810/rr-2
198. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med [Internet]. 2020 Mar;2600(20):30116. Available from: http://dx.doi.org/10.1016/S2213-2600(20)30116-8
199. Gurwitz D. Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics. Drug Dev Res [Internet]. 2020;(February):2–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32129518
200. Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol [Internet]. 2020 Mar 27; Available from: https://jamanetwork.com/journals/jamacardiology/fullarticle/2763845
201. Cardiologia SE de. No hay evidencia clínica ni científica para suspender tratamientos de IECA y ARA debido a la infección por COVID-19 [Internet]. 2020 [cited 2020 Mar 15]. Available from: https://secardiologia.es/institucional/socios/comunicados/comunicados-oficiales/11446-no-hay-evidencia-clinica-ni-cientifica-para-suspender-tratamientos-de-ieca-y-ara-debido-a-la-infeccion-por-covid-19
202. Vaduganathan M, Vardeny O, Michel T, McMurray JJV, Pfeffer MA, Solomon SD. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med [Internet]. 2020 Mar 30;NEJMsr2005760. Available from: http://www.nejm.org/doi/10.1056/NEJMsr2005760
203. European medicines agency. EMA advises continued use of medicines for hypertension, heart or kidney disease during COVID-19 pandemic [Internet]. 2020 [cited 2020 Apr 5]. Available from: https://www.ema.europa.eu/en/news/ema-advises-continued-use-medicines-hypertension-heart-kidney-disease-during-covid-19-pandemic
204. Greenhalgh T, Koh GCH, Car J. Covid-19: a remote assessment in primary care. BMJ [Internet]. 2020;368(March):m1182. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32213507
205. Alfageme, J. Aspa, S. Belloa, J. Blanquerb, R. Blanquer, L. Bor-derías, C. Bravo, R. de Celis, X. de Gracia, J. Dorcac, J. Gallardo, M.Gallego, R. Menéndeza, L. Molinosa, C. Paredes, O. Rajas, J. Rello, F. Rodríguez de Castrob, J. Roig, F. Sánchez-Gascón ATRZ. Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología Normativas para el diagnóstico y el tratamiento de la neumonía adquirida en la comunidad. Sociedad Española de Neumología y Cirugía T. Arch Bronconeumol. 2005;41(5):272–89.
206. Molero García JM, Eugenia Carandell Jäger M, Cots Yago JM, Llor C, Muñoz Gutiérrez J, Paredes Saura J, et al. Infecciones del aparato respiratorio inferior.
207. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet (London, England) [Internet]. 2020;6736(20):1–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32171076
208. Halem K Van, Cox J, Messiaen P, Pat K, Declercq C, Meersman A. Care for adult non-ICU Covid-19 patients : early experiences from a Belgian tertiary care centre. 2020;78(3):111–5.
209. SEMFYC. Continuidad asistencial al alta en pacientes con diagnóstico de neumonía por SARS-COV-2. Conciliación de la medicación. 2020.
210. Ministerio de Sanidad Servicios Sociales e Igualdad. Manejo domiciliario del COVID-19 [Internet]. Madrid; Available from: https://www.mscbs.gob.es/en/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Manejo_domiciliario_de_COVID-19.pdf
211. World Health Organization. Home care for patients with suspected novel coronavirus ( nCoV ) infection presenting with mild symptoms and management of contacts. Who. 2020;(January):4–6.
212. CDC. Discontinuation of Home Isolation for Persons with COVID-19. 2020.
213. CDC. Criteria for Return to Work for Healthcare Personnel with Confirmed or Suspected COVID-19 (Interim Guidance). 2020.
214. Ding J, Tuan W-J, Temte JL. Managing Close Contacts of COVID-19 Confirmed Cases in Metropolitan Areas in China. J Public Heal Manag Pract [Internet]. 2020 Apr;1. Available from: http://journals.lww.com/10.1097/PHH.0000000000001189
215. Milagros Martí de Gracia. Imaging the coronavirus disease COVID-19 [Internet]. Healthcare in Europe.com. 2020 [cited 2020 Apr 4]. Available from: https://healthcare-in-europe.com/en/news/imaging-the-coronavirus-disease-covid-19.html
216. Gómez- Batiste X et al. Recomendaciones éticas y clínicas para la toma de decisiones en el entorno residencial en el contexto de la crisis de COVID-19. 2020.
217. European Association of Palliative Care. Coronavirus and the palliative care response [Internet]. Available from: ttps://www.eapcnet.eu/publications/coronavirus-and-the-palliative-care-response
218. Nouvet E, Sivaram M, Bezanson K, Krishnaraj G, Hunt M, de Laat S, et al. Palliative care in humanitarian crises: a review of the literature. J Int Humanit Action [Internet]. 2018 Dec 20;3(1):5. Available from: https://jhumanitarianaction.springeropen.com/articles/10.1186/s41018-018-0033-8
219. Downar J, Seccareccia D, Associated Medical Services Inc. Educational Fellows in Care at the End of Life. Palliating a pandemic: “all patients must be cared for”. J Pain Symptom Manage [Internet]. 2010 Feb;39(2):291–5. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20152591
220. Afilliated T first hospital ZUS o. Handbook of COVID-19 Prevention and Treatment. 2020.
221. Rodríguez JPSXGBAT. Manual de control de síntomas en pacientes con cáncer avanzado y terminal 3a Edición.
222. MacLeod, Roderick Duncan, Van den Block L. Textbook of Palliative care. Springer, editor.
223. Secpal. Guía de sedación paliativa.
224. Alonso-Babarro A, Varela-Cerdeira M, Torres-Vigil I, Rodríguez-Barrientos R, Bruera E. At-home palliative sedation for end-of-life cancer patients. Palliat Med [Internet]. 2010 Jul;24(5):486–92. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20133320
225. Alonso MÁM. FLUIDOTERAPIA INTRAVENOSA EN URGENCIAS Y EMERGENCIAS. [Internet]. [cited 2020 Mar 22]. Available from: http://www.medynet.com/usuarios/jraguilar/Manual de urgencias y Emergencias/fluido.pdf
226. Frost P. Intravenous fluid therapy in adult inpatients. BMJ [Internet]. 2015 Jan 6;350:g7620. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25569336
227. Salud Herrera Adán, Marta Egea Simón SMZ. Agua, fluidoterapia y osmolaridad [Internet]. [cited 2020 Mar 22]. Available from: http://www.ffis.es/volviendoalobasico/4anexo_fluidoterapia.html
228. Autores V. Medimecum, Guía de terapia farmacológica. Springer; 2019.
229. R Bugarín González JBMR. La oxigenoterapia en situaciones graves. Med Integr. 2000;36(5):159–65.
230. Chiner Vives, Eusebi; Giner Donaire J. Sistemas de oxigenoterapia. Manual Separ Procedimientos. 2014.
231. Jimenez Murillo; Montero Perez. Medicina de Urgencias y Emergencias. 2018.
232. SAMUR. Manual de procedimientos operativos. 2019.
233. Trampal A. MM. Guía de valoración y tratamiento parenteral para enfermería. Trampal; 2011.
234. Henry BM, Lippi G. Chronic kidney disease is associated with severe coronavirus disease 2019 (COVID-19) infection. Int Urol Nephrol [Internet]. 2020 Mar 28;2019(PG-105941-105941):105941. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0954611120300810 NS -
235. Instituto superiore di sanitá. Characteristics of COVID-19 patients dying in Italy th Report based on available data on March 20 , 2020. 2020.
236. Huang I, Lim MA, Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia – A systematic review, meta-analysis, and meta-regression: Diabetes and COVID-19. Diabetes Metab Syndr Clin Res Rev [Internet]. 2020;14(4):395–403. Available from: https://doi.org/10.1016/j.dsx.2020.04.018
237. Fadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest [Internet]. 2020;(0123456789):2–4. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32222956
238. Kokic Males V. Letter to the Editor in response to the article “COVID-19 and diabetes: Can DPP4 inhibition play a role?” Diabetes Res Clin Pract [Internet]. 2020 Apr;108163. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0168822720304137
239. Cook TM. Hypertension is a clinically important risk factor for severe illness and mortality in COVID‐19. Anaesthesia [Internet]. 2020 Apr 27;anae.15103. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/anae.15103
240. Prevention C for DC and. Are You at Higher Risk for Severe Illness? | CDC. 2020.
241. Zhang B, Zhou X, Qiu Y, Feng F, Feng J, Jia Y, et al. Clinical characteristics of 82 death cases with COVID-19. medRxiv. 2020 Feb;2020.02.26.20028191.
242. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents. 2020;2:105924.
243. Wang W, Tang J, Wei F. Updated understanding of the outbreak of 2019 novel coronavirus (2019‐nCoV) in Wuhan, China. J Med Virol. 2020 Apr;92(4):441–7.
244. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar;
245. Lian J, Jin X, Hao S, Cai H, Zhang S, Zheng L, et al. Analysis of Epidemiological and Clinical features in older patients with Corona Virus Disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis [Internet]. 2020 Mar 25;53(9):1689–99. Available from: https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciaa242/5811557
246. YajunYuan, Wang N, Ou X. Caution should be exercised for the detection of SARS-CoV-2, especially in the elderly. J Med Virol [Internet]. 2020 Mar 30; Available from: http://doi.wiley.com/10.1002/jmv.25796
247. Ministerio de Sanidad Servicios Sociales e Igualdad. Actualización no 66. Enfermedad por el coronavirus (COVID-19), 05/04/2020 [Internet]. 2020. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/documentos/Actualizacion_66_COVID-19.pdf
248. Bonanad C, García-Blas S, Díez-Villanueva P et al. Coronavirus en el paciente mayor: una emergencia geriátrica SEC.
249. Díez-Villanueva P, Arizá-Solé A, Vidán MT, Bonanad C, Formiga F, Sanchis J, et al. Recomendaciones de la Sección de Cardiología Geriátrica de la Sociedad Española de Cardiología para la valoración de la fragilidad en el anciano con cardiopatía. Rev Española Cardiol [Internet]. 2019 Jan;72(1):63–71. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0300893218303579
250. Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol [Internet]. 2020 Apr 25;jrheum.200507. Available from: http://www.jrheum.org/lookup/doi/10.3899/jrheum.200507
251. SEIMC.SEI. Recomendaciones de la SEIMC-SEI para la prevención frente al coronavirus SARS-COV-2 en pacientes inmunodeprimidos. 2020.
252. Shen KL, Yang YH. Diagnosis and treatment of 2019 novel coronavirus infection in children: a pressing issue. World J Pediatr [Internet]. 2020;(2):6–8. Available from: https://doi.org/10.1007/s12519-020-00344-6
253. Cao Q, Chen YC, Chen CL, Chiu CH. SARS-CoV-2 infection in children: Transmission dynamics and clinical characteristics. J Formos Med Assoc [Internet]. 2020;119(3):670–3. Available from: https://doi.org/10.1016/j.jfma.2020.02.009
254. Philippe Colson, Hervé Tissot-Dupont, Aurélie Morand, Céline Boschi, Laetitia Ninove, Vera Esteves-Viera PG, , Philippe Brouqui, Philippe Parola, Jean-Christophe Lagier, Christine Zandotti, Matthieu Million, Bernard La Scola DR. Children account for a small proportion of diagnoses of SARS-CoV-2 infection and do not exhibit greater viral loads than adult. Pendiente de envio. 2020;
255. Qiu H, Wu J, Hong L, Luo Y, Song Q, Chen D. Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study. Lancet Infect Dis [Internet]. 2020 Mar; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1473309920301985
256. Dong Y, Mo X, Hu Y, Qi X, Jiang F, Jiang Z, et al. Epidemiology of COVID-19 Among Children in China. Pediatrics [Internet]. 2020 Mar 16;e20200702. Available from: http://pediatrics.aappublications.org/lookup/doi/10.1542/peds.2020-0702
257. Molloy EJ, Bearer CF. COVID-19 in children and altered inflammatory responses. Pediatr Res [Internet]. 2020 Apr 3; Available from: http://www.nature.com/articles/s41390-020-0881-y
258. Ma X, Su L, Zhang Y, Zhang X, Gai Z, Zhang Z. Do children need a longer time to shed SARS-CoV-2 in stool than adults? J Microbiol Immunol Infect [Internet]. 2020 Mar; Available from: https://linkinghub.elsevier.com/retrieve/pii/S1684118220300700
259. Brodin P. Why is COVID-19 so mild in children? Acta Paediatr [Internet]. 2020 Mar 25; Available from: http://doi.wiley.com/10.1111/apa.15271
260. Mazzotta F. TT. ACUTE ACRO-ISCHEMIA IN THE CHILD AT THE TIME OF COVID-19. Dermatologia Pediatr [Internet]. 2020; Available from: http://sectcv.es/wp-content/uploads/2020/04/acroischemia-ENG.pdf
261. Zhang Y, Cao W, Xiao M, Li YJ, Yang Y, Zhao J, et al. Clinical and coagulation characteristics of 7 patients with critical COVID-2019 pneumonia and acro-ischemia. Zhonghua Xue Ye Xue Za Zhi [Internet]. 2020 Mar 28;41:E006. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32220276
262. Laforgia N. GL. Neonatal gangrene. Eur J Pediat Dermatol. 2009;19(3):157.
263. AEDV. La AEDV colabora con el estudio COVID-Piel que se acaba de poner en marcha en España [Internet]. [cited 2020 Apr 13]. Available from: https://aedv.es/la-aedv-colabora-con-el-estudio-covid-piel-que-se-acaba-de-poner-en-marcha-en-espana/?utm_source=Doppler&utm_medium=email&utm_campaign=AEDV+Especial+%7C+Coronavirus+2+Académicos&dplrid=5274616265726E657240676D61696C2E636F6D
264. Folkehelseinstituttet/Norwegian Institute of Public Health. The role of children in the transmission of SARS-CoV-2 (COVID-19) – a rapid review. 2020.
265. Wong SF, Chow KM, Leung TN, Ng WF, Ng TK, Shek CC, et al. Pregnancy and perinatal outcomes of women with severe acute respiratory syndrome. Am J Obstet Gynecol [Internet]. 2004 Jul;191(1):292–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15295381
266. Chen H, Guo J, Wang C, Luo F, Yu X, Zhang W, et al. Clinical characteristics and intrauterine vertical transmission potential of COVID-19 infection in nine pregnant women: a retrospective review of medical records. Lancet [Internet]. 2020;395(10226):809–15. Available from: http://dx.doi.org/10.1016/S0140-6736(20)30360-3
267. CDC. COVID-19 Pregnancy and Breastfeeding [Internet]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fspecific-groups%2Fpregnancy-faq.html
268. Yan J, Guo J, Fan C, Juan J, Yu X, Li J, et al. Coronavirus disease 2019 (COVID-19) in pregnant women: A report based on 116 cases. Am J Obstet Gynecol [Internet]. 2020 Apr; Available from: https://linkinghub.elsevier.com/retrieve/pii/S0002937820304622
269. Lu Q, Shi Y. Coronavirus disease (COVID‐19) and neonate: What neonatologist need to know. J Med Virol [Internet]. 2020 Mar 12;jmv.25740. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/jmv.25740
270. Hu X, Gao J, Luo X, Feng L, Liu W, Chen J, et al. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vertical Transmission in Neonates Born to Mothers With Coronavirus Disease 2019 (COVID-19) Pneumonia. Obstet Gynecol [Internet]. 2020 Apr;1. Available from: http://journals.lww.com/10.1097/AOG.0000000000003926
271. CDC. Pregnancy & Breastfeeding | Information about Coronavirus Disease 2019 [Internet]. 2020 [cited 2020 Mar 15]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/prepare/pregnancy-breastfeeding.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fspecific-groups%2Fpregnancy-faq.html
272. Mallada PL, Díaz Gómez M, San L, Martín F, Romero MC, Carme M, et al. MANEJO DEL RIESGO DE CONTAGIO POR CORONAVIRUS EN MADRES Y RECIÉN NACIDOS [Internet]. Available from: http://aelama.org/wp-content/uploads/2020/03/Lactancia-y-coronavirus-2020.pdf
273. Lupia T, Scabini S, Pinna SM, Di Perri G, De Rosa FG, Corcione S. 2019-novel coronavirus outbreak: A new challenge. J Glob Antimicrob Resist [Internet]. 2020; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32156648
274. Wang Y, Di Y, Ye J, Wei W. Study on the public psychological states and its related factors during the outbreak of coronavirus disease 2019 (COVID-19) in some regions of China. Psychol Health Med [Internet]. 2020;8506:1–10. Available from: http://www.ncbi.nlm.nih.gov/pubmed/32223317
275. Pristerà P, Papageorgiou V, Kaur M, Atchison C, Redd R, Bowman L. Report 14 : Online Community Involvement in COVID-19 Research & Outbreak Response : Early Insights from a UK Perspective. 2020;(April):1–31.
276. Psiquiatría SE de. Cuidando la salud mental del personal sanitario [Internet]. 2020. Available from: www.sepsiq.org
277. Galatea. Información contacto Galatea [Internet]. 2020. Available from: https://www.fgalatea.org/es/ajut-pscicologic.php
278. Atchison C, Bowman L, Eaton JW, Imai N, Redd R, Pristera P, et al. Public Response to UK Government Recommendations on COVID-19: Population Survey, 17-18 March 2020. Imp Coll London COVID-19 Response Team [Internet]. 2020;(March 20):17–8. Available from: https://www.imperial.ac.uk/mrc-global-infectious-disease-analysis/news--wuhan-coronavirus/
279. SEI. SEIP. AEP. Otros efectos de la pandemia de COVID-19: caída de las vacunaciones [Internet]. 2020. Available from: https://vacunasaep.org/profesionales/noticias/otros-efectos-de-la-pandemia-de-covid-19-caida-de-las-vacunaciones
280. Ministerio de Sanidad Servicios Sociales e Igualdad. Prioridades del programa de vacunación durante el estado de alarma debido a COVID-19 [Internet]. 2020. Available from: https://www.mscbs.gob.es
281. Lim SM, Cha WC, Chae MK, Jo IJ. Contamination during doffing of personal protective equipment by healthcare providers. Clin Exp Emerg Med [Internet]. 2015 Sep;2(3):162–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27752591
282. National Institute for Occupational Safety and Health. Recommended Guidance for Extended Use and Limited Reuse of N95 Filtering Facepiece Respirators in Healthcare Settings Centers for Disease Control and Prevention. 2018.
283. Fisher EM, Shaffer RE. Considerations for Recommending Extended Use and Limited Reuse of Filtering Facepiece Respirators in Health Care Settings. J Occup Environ Hyg [Internet]. 2014 Aug 3;11(8):D115–28. Available from: http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&DbFrom=pubmed&Cmd=Link&LinkName=pubmed_pubmed&LinkReadableName=Related Articles&IdsFromResult=24628658&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
284. WHO. Rational use of personal protective equipment for coronavirus disease 2019 (COVID-19) 2020 [Internet]. 2020 [cited 2020 Feb 28]. Available from: https://apps.who.int/iris/bitstream/handle/10665/331498/WHO-2019-nCoV-IPCPPE_use-2020.2-eng.pdf
285. Ministerio de Sanidad Servicios Sociales e Igualdad. Recomendaciones sobre el uso de mascarillas en la comunidad en el contexto de COVID-19 [Internet]. 2020. Available from: www.mscbs.gob.es
286. Stanford University Anesthesia Informatics and Media. COVID 19 Evidence Service. Report p 5 Retrieved 25.
287. Preevid. Murcia Salud. Uso de mascarillas de realización casera por parte de los profesionales sanitarios. [Internet]. 2020 [cited 2020 Mar 28]. Available from: http://www.murciasalud.es/preevid/23550
288. (CDC). C for disease control and prevention. Coranavirus disease (COVID-19). Strategies for Optimizing the Supply of Facemasks. [Internet]. 2020 [cited 2020 Mar 28]. Available from: https//:www.cdcgovcoronavirusncovhcpppestrategyfacemasks.html
289. Ma Q-X, Shan H, Zhang H-L, Li G-M, Yang R-M, Chen J-M. Potential utilities of mask wearing and instant hand hygiene for fighting SARS-CoV-2. J Med Virol [Internet]. 2020 Mar 31; Available from: http://www.ncbi.nlm.nih.gov/pubmed/32232986
290. Taberner R. ¿Cómo afecta el COVID-19 a la piel? Consejos para sanitarios y pacientes [Internet]. Blog ( internet). 2020 [cited 2020 Apr 4]. Available from: https://www.dermapixel.com/2020/03/como-afecta-el-covid-19-la-piel.html
291. Amazing Science. This gives you an idea how many layers of protection doctors must protect themselves everyday from the corona virus. [Internet]. Twitter. 2020 [cited 2020 Apr 1]. Available from: https://twitter.com/AMAZlNGSCIENCE/status/1244283402750013442
292. C OT. Compra el stick de Compeed para las rozaduras. Aplícatelo unos minutos antes de ponerte la mascarilla. Te cambiará la vida. Si se ha roto la piel, los apósitos hidrocoloides que se usan para UPP. También cortadas en tiras, para el tabique nasal con la mas [Internet]. Twitter, 25/03/2020. 2020 [cited 2020 Apr 4]. Available from: https://twitter.com/dra_dixit/status/1243943189695913984
293. C OT. Veo muchos sufriendo porque se les empañaban las gafas con las mascarillas. Ajuste mascarilla: dedos corazón en la nariz y apretando con ambos índices a los laterales. Soplar después fuerte, y asegurarse de que no salga aire hacia arriba. Ajuste gafas: ag [Internet]. Twitter, 20/03/2020. 2020. Available from: 04/04/2020
Última actualización